Processing

Please wait...

Settings

Settings

Goto Application

1. WO2015083130 - FUSED PYRIDINE AND PYRIMIDINE DERIVATIVES AS ROR GAMMA MODULATORS

Publication Number WO/2015/083130
Publication Date 11.06.2015
International Application No. PCT/IB2014/066635
International Filing Date 05.12.2014
IPC
A61K 31/427 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
425Thiazoles
427not condensed and containing further heterocyclic rings
A61P 37/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
37Drugs for immunological or allergic disorders
A61P 3/10 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3Drugs for disorders of the metabolism
08for glucose homeostasis
10for hyperglycaemia, e.g. antidiabetics
C07D 333/38 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
333Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
02not condensed with other rings
04not substituted on the ring sulfur atom
26with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
38Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
CPC
A61P 3/10
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3Drugs for disorders of the metabolism
08for glucose homeostasis
10for hyperglycaemia, e.g. antidiabetics
A61P 37/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
37Drugs for immunological or allergic disorders
C07D 209/96
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
209Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
56Ring systems containing three or more rings
96Spiro-condensed ring systems
C07D 215/20
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
215Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
02having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
16with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
20Oxygen atoms
C07D 239/72
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
239Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
70condensed with carbocyclic rings or ring systems
72Quinazolines; Hydrogenated quinazolines
C07D 401/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02containing two hetero rings
10linked by a carbon chain containing aromatic rings
Applicants
  • AURIGENE DISCOVERY TECHNOLOGIES LIMITED [IN]/[IN]
Inventors
  • KOTRABASAIAH UJJINAMATADA, Ravi
  • SAMAJDAR, Susanta
  • HOSAHALLI, Subramanya
  • BEJUGAM, Mallesham
Priority Data
5641/CHE/201306.12.2013IN
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) FUSED PYRIDINE AND PYRIMIDINE DERIVATIVES AS ROR GAMMA MODULATORS
(FR) PYRIDINE ET DÉRIVÉS DE PYRIMIDINE À L'ÉTAT FONDU À TITRE DE MODULATEURS ROR GAMMA
Abstract
(EN) The present invention provides fused pyridine and pyrimidine derivatives of formula (I), which may be therapeutically useful, more particularly as RORγ modulators; in which Ra, Rb, A, B, X, P, Q, L, R4, R5 and m have the meanings given in the specification, and pharmaceutically acceptable salts thereof that are useful in the treatment and prevention of diseases or disorder, in particular their use in disease(s) or disorder(s) where there is an advantage in modulating RORγ receptor. The present invention also provides preparation of the compounds and pharmaceutical formulations comprising at least one of the fused pyridine and pyrimidine derivatives of formula (I), together with a pharmaceutically acceptable carrier, diluent or excipient therefor.
(FR) Cette invention concerne une pyridine et des dérivés de pyrimidine à l'état fondu de formule (I), qui peuvent être thérapeutiquement utiles, plus particulièrement à titre de modulateurs RORγ ; Ra, Rb, A, B, X, P, Q, L, R4, R5 et m dans la formule ayant les significations indiquées dans la description, et leurs sels pharmaceutiquement acceptables qui sont utiles pour traiter et prévenir des maladies ou des troubles, en particulier leur utilisation dans une ou des maladies ou un ou des troubles où la modulation du récepteur RORγ présente un avantage. La préparation des composés selon l'invention et de formulations pharmaceutiques comprenant au moins la pyridine et/ou l'un de ses dérivés à l'état fondu de formule (I), associés à un véhicule, un diluant, ou un excipient pharmaceutiquement acceptable pour ceux-ci est en outre décrite.
Latest bibliographic data on file with the International Bureau